Biography
Dr. Quong is the Chief Science Officer, and he serves as liaison and bridge to the research community, identifying opportunities to address unmet needs in human health. He is the primary point of contact to pharma industry consortia and other avenues of global collaboration and plays a key role on establishing product roadmaps and broad product development priorities as well as potential partnership, licensing, and acquisition opportunities. Previously he was the Director of Strategic Scientific Initiatives and Partnerships at the Frederick National Laboratory for Cancer Research and was a faculty member in the Department of Cancer Biology at Thomas Jefferson University and the Department of Oncology at Georgetown University. His research focused on systems biology approaches to understanding mechanisms of resistance to treatment of breast cancer and biomarkers of response. He has published extensively and served on the editorial boards of Cancer Research and The American Journal of Pathology.

Clinical & Research Tools Showcase:
Fluidigm
Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all.

Reimagining High-content Immune Profiling for Clinical Research
Time and samples are precious commodities when it comes to clinical research, particularly for large cohorts.  Learn about the advantages of easy workflows for high-parameter assays, minimal sample volumes and automated analysis with Fluidigm’s CyTOF XT® and immune profiling solutions.